Trial · NCT07882589
Psychoactive Drug Use and Acute Care Use After Trauma and Out-of-Hospital Cardiac Arrest
NCT07882589, Active not recruiting, Azienda Usl di Bologna
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Psychoactive Drug Use and Acute Care Use After Trauma and Out-of-Hospital Cardiac Arrest. Trials, record NCT07882589. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882589
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Psychoactive Drug Use and Acute Care Use After Trauma and Out-of-Hospital Cardiac Arrest
- NCT number
- NCT07882589
- Status
- Active not recruiting
- Enrollment
- 52,720 participants, estimated
- Lead sponsor
- Azienda Usl di Bologna
- Conditions
- Wounds and Injuries, Out-of-Hospital Cardiac Arrest, Traumatic Brain Injury
- Interventions
- Opioids (ATC N02A), Antiepileptics (ATC N03A), Antipsychotics (ATC N05A), Antidepressants (ATC N06A)
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Patients With Post-discharge Exposure to Each Psychoactive Drug Class | 1 year after hospital discharge | Percentage of patients with at least one qualifying post-discharge treatment episode (treatment initiation, continuation, or restart within 30 days of discharge) for each drug class: opioids (ATC N02A), antiepileptics (N03A), antipsychotics (N05A), and antidepressants (N06A), derived from outpatient dispensing records and reported separately for each cohort. |
| Primary | Percentage of Exposed Patients by User Type for Each Psychoactive Drug Class | 1 year after hospital discharge | Among patients exposed to each drug class (opioids, antiepileptics, antipsychotics, antidepressants) before admission and/or after discharge, percentage of naive users (exposure after discharge only), long-term users (exposure both before admission and after discharge), and interrupted users (exposure before admission only, not continued after discharge), reported separately for each cohort. |
| Primary | Percentage of New Users by Duration of Post-discharge Treatment for Each Psychoactive Drug Class | 1 year after hospital discharge | Among naive users of each drug class (opioids, antiepileptics, antipsychotics, antidepressants), percentage whose qualifying post-discharge treatment episode lasted up to 30 days, 31-90 days, or 91-365 days (episode span, with dispensings chained using a 60-day grace period), reported separately for each cohort. |
| Secondary | Number of low-acuity or incomplete emergency department visits | 1 year after hospital discharge | Count of emergency department visits with a missing, non-urgent, or minor-urgency discharge severity code, with the patient leaving before the medical visit or before record closure, or with a missing or supplementary-classification (ICD-9-CM V code) diagnosis, excluding scheduled or routine contacts; analysed as incidence rate ratios by post-discharge exposure state. |
| Secondary | Number of urgent hospital readmissions | 1 year after hospital discharge | Count of urgent ordinary-regime hospital admissions, excluding scheduled or routine contacts; analysed as incidence rate ratios by post-discharge exposure state. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882589
GET https://conductscience.org/api/trials/v1/NCT07882589/registered